Keros Therapeutics Inc KROS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $11.64
- Day Range
- $11.49–12.26
- 52-Week Range
- $9.69–22.55
- Bid/Ask
- $11.00 / $12.00
- Shares Outstanding
- 19.83M
- Market Cap
- $236.93M
- Volume/Avg
- 194,392 / 196,787
Key Statistics
- Price/Earnings (Normalized)
- 6.57
- Price/Sales
- 21.60
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 158.27%
Company Profile
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 92
- Website
- https://www.kerostx.com
Valuation
|
Metric
|
KROS
|
|---|---|
Price/Earnings (Normalized) | 6.57 |
Price/Book Value | 0.90 |
Price/Sales | 21.60 |
Price/Cash Flow | — |
Price/Earnings
KROS
Financial Strength
|
Metric
|
KROS
|
|---|---|
Quick Ratio | 21.42 |
Current Ratio | 21.96 |
Interest Coverage | — |
Quick Ratio
KROS
Profitability
|
Metric
|
KROS
|
|---|---|
Return on Assets (Normalized) | −12.53% |
Return on Equity (Normalized) | −13.50% |
Return on Invested Capital (Normalized) | −16.22% |
Return on Assets
KROS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|GB@qnQY | LOCK|<#N& | $129B | |||
| Moderna Inc
MRNA
| LOCK|&b#WTr | LOCK|Bk | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|cDCksC! | LOCK|P<^N@ | $77B | |||
| argenx SE ADR
ARGX
| LOCK|!Tbt!& | LOCK|f# | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|!rg&QH | LOCK|bYp | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|zVc?J<? | LOCK|&xR%> | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|hP&yfzJ | LOCK|Nl?jb | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|>gV&D< | LOCK|P? | $24B | |||
| Incyte Corp
INCY
| LOCK|GKNM$c | LOCK|yw | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|Gysymv# | LOCK|G^t | $14B |
United States